Related Experiment Video

Updated: Aug 11, 2026

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

Atrial fibrillation and congestive heart failure: risk factors, mechanisms, and treatment

E Kevin Heist1, Jeremy N Ruskin

  • 1Cardiac Arrhythmia Service, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.

Progress in Cardiovascular Diseases
|March 7, 2006
PubMed

Insights

Atrial fibrillation (AF) and congestive heart failure (CHF) often coexist, sharing risk factors and underlying mechanisms. Treatments range from medications and devices to ablation and novel biologic therapies.

Area of Science:

  • Cardiology
  • Internal Medicine

Background:

  • Atrial fibrillation (AF) and congestive heart failure (CHF) are frequently comorbid conditions.
  • Shared risk factors include age, hypertension, and myocardial infarction.
  • Common pathophysiological mechanisms involve myocardial fibrosis and intracellular dysregulation.

Purpose of the Study:

  • To review the relationship between AF and CHF.
  • To discuss shared risk factors and mechanisms.
  • To outline current and emerging treatment strategies.

Main Methods:

  • Literature review of studies on AF and CHF.
  • Analysis of shared etiological factors and pathophysiological pathways.
  • Evaluation of pharmacological, device-based, and interventional therapies.

Main Results:

  • Both AF and CHF share common risk factors and underlying mechanisms.
  • Pharmacological treatments like beta-blockers and ACE inhibitors are beneficial for both.
  • Device therapies (pacemakers, CRT) and ablation offer therapeutic options.
  • Investigational cell and gene therapies show future promise.

Conclusions:

  • AF and CHF are interconnected conditions with overlapping pathophysiology.
  • A multifaceted treatment approach combining medications, devices, and interventions is often necessary.
  • Future biologic therapies hold potential for addressing core disease mechanisms.

More Related Videos

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Estimating Bilateral Atrial Function by Cardiovascular Magnetic Resonance Feature Tracking in Patients with Paroxysmal Atrial Fibrillation08:10

Estimating Bilateral Atrial Function by Cardiovascular Magnetic Resonance Feature Tracking in Patients with Paroxysmal Atrial Fibrillation

Published on: July 20, 2022

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...